Candel Therapeutics’ CAN-2409 Achieves 50% 24-Month Survival and 25.4-Month Median OS
Updated Phase 2a data for Candel Therapeutics’ CAN-2409 showed 50% of 46 NSCLC patients alive at 24 months and median overall survival of 25.4 months versus historical 9.8–11.8 months. Survival rates reached 35% at 30 months, 26% at 36 months and 13% at 50 months.
1. Extended Survival Outcomes
Candel Therapeutics reported that 50% of 46 patients remained alive 24 months after CAN-2409 treatment in its Phase 2a NSCLC trial, up from 39% at the earlier data cut. Survival rates reached 35% at 30 months, 26% at 36 months, 24% at 40 months and 13% at 50 months.
2. Median Overall Survival and Historical Comparison
Median overall survival across cohorts 1 and 2 reached 25.4 months, with a subgroup of prior ICI non-responders recording 21.5 months and non-squamous histology patients also at 25.4 months. These outcomes compare with historical mOS of 9.8 to 11.8 months for standard-of-care docetaxel.
3. Biomarker and Immune Response Findings
Biomarker analyses showed that 85% of long-term survivors had baseline PD-L1 scores below 50%, a group typically less responsive to ICIs. Post-treatment biopsies revealed increased pro-inflammatory gene expression, activation of interferon signaling and expanded T-cell receptor diversity in tumor tissue and blood.
4. Safety and Tolerability Profile
CAN-2409 maintained a generally favorable tolerability profile over the extended follow-up, with no new safety signals reported and side effects consistent with earlier trial observations.